Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958562 | 0.77 | L3MBTL1 (0.35) | L3MBTL1 | |
| SCHEMBL7132351 | 0.74 | L3MBTL1 (0.46) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL23531699 | 0.72 | DAO (0.42) | L3MBTL1 | |
| SCHEMBL25138993 | 0.70 | — | — | |
| SCHEMBL22014384 | 0.69 | — | — | |
| SCHEMBL15880558 | 0.69 | LOX (0.48) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL18090589 | 0.67 | NPSR1 (0.74) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL8870484 | 0.65 | CA2 (0.52) | L3MBTL1 | |
| SCHEMBL16732 | 0.65 | KMT2A (0.50) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL29512560 | 0.64 | MAPT (0.47) | LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | LMNA 1423/4885PPARG 4045/4885NCOA2 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.